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Although many antipsychotics can reasonably control positive symptoms in schizophrenia,
patients’ return to society is often hindered by negative symptoms and cognitive deficits.
As an alternative to animal rodent models that are often not very predictive for the clinical
situation, we developed a new computer-based mechanistic modeling approach. This
Quantitative Systems Pharmacology approach combines preclinical basic neurophysiology
of a biophysically realistic neuronal ventromedial cortical-ventral striatal network identified
from human imaging studies that are associated with negative symptoms. Calibration
of a few biological coupling parameters using a retrospective clinical database of 34
drug-dose combinations resulted in correlation coefficients greater than 0.60, while a
robust quantitative prediction of a number of independent trials was observed. We then
simulated the effect of glycine modulation on the anticipated clinical outcomes. The
quantitative biochemistry of glycine interaction with the different NMDA-NR2 subunits,
neurodevelopmental trajectory of the NMDA-NR2B in the human schizophrenia pathology,
their specific localization on excitatory vs. inhibitory interneurons and the electrogenic
nature of the glycine transporter resulted in an inverse U-shape dose-response with an
optimum in the lowmicromolar glycine concentration. Quantitative systems pharmacology
based computer modeling of complex humanized brain circuits is a powerful alternative
approach to explain the non-monotonic dose-response observed in past clinical trial
outcomes with sarcosine, D-cycloserine, glycine, or D-serine or with glycine transporter
inhibitors. In general it can be helpful to better understand the human neurophysiology of
negative symptoms, especially with targets that show non-monotonic dose-responses.
Keywords: schizophrenia, negative symptoms, glycine, computer model, dose-response relationship, drug
INTRODUCTION
Negative symptoms in schizophrenia are a major cause of func-
tional deficit for patients wanting to return to professional life.
While many of the approved antipsychotics can control the
positive symptoms, negative symptom dysfunction is often not
addressed properly by drug therapy alone (Rosenbaum et al.,
2012). In addition, there are species differences for animal
models that have large ramifications for drug development in
Abbreviations: ASL-fMRI, Arterial Spin Labeling functional Magnetic Resonance
Imaging; BOLD-fMRI, Blood Oxygen Level Dependent functional Magnetic
Resonance Imaging; CBF, Cerebral Blood flow; DA, Dopamine; dlPFC, dorso-
lateral Prefrontal Cortex; EC50, concentration at which 50% of maximal effect is
reached; Enk, encephalin; ER, endoplasmic reticulum; GlyT1, Glycine Transporter
subtype 1; mAChR, muscarinic acetylcholine receptor; mGluR, metabotropic glu-
tamate receptor; MSN, Medium Spiny Neuron (major cell type in striatum);
NMDA, N-methyl-D-aspartate (glutamate receptor subtype); PANSS, Positive and
Negative Symptoms Scale in schizophrenia; PDSP, Psycho-active Drug Screening
Program; PET, Positron Emission Tomography; PFC, Prefrontal Cortex; PSD-
95, postsynaptic density complex; QSP, Quantitative Systems Pharmacology; SP,
Substance P; vmPFC, ventro-medial Prefrontal Cortex.
schizophrenia (Peleg-Raibstein et al., 2012) and consequently
psychiatric disorders have one of the lowest probabilities of
clinical success, close to 7% (Hay et al., 2014). Because of
these limitations, companies are de-emphasizing psychiatric dis-
eases (Hyman, 2014), suggesting a need for completely novel
technologies.
Negative symptoms can be divided in two moderately cor-
related factors (Horan et al., 2011): experiential impairments
(diminished motivation and enjoyment of social, vocational, and
recreational activities) and expressive impairments (diminished
non-verbal and verbal communication). Experiential impair-
ments are best represented by avolition and anhedonia, while
expressive impairments are related to flat affect. Both these
dimensions play an important role in the clinical phenotype.
Glutamate modulation through increased glycine mediated
stimulation of the NMDA-R has been proposed as a strategy for
addressing negative symptoms in schizophrenia. Consequently,
a number of glycine modulators have been studied in clinical
trials. In humans, the GlyT1 inhibitor ORG25935 reduced
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the ketamine-induced increases in measures of psychosis and
perceptual alterations with an effect size of 0.71 and 0.98,
respectively, but worsened some aspects of learning and delayed
recall (D’Souza et al., 2012). Studies with the GlyT1 inhibitor
GSK1018921 suggested that target engagements up to 80% were
well tolerated (Ouellet et al., 2011). The Janssen GlyT1 inhibitor
R213129 enhanced scopolamine-induced finger tapping impair-
ment in healthy volunteers, while electroencephalography alpha
power was increased and scopolamine-induced impairment
of the Stroop test was partly reversed (Liem-Moolenaar et al.,
2010). The Pfizer GlyT1 inhibitor PF03463275 was ineffective
at the highest dose (NIH NCATS website http://www.ncats.nih.
gov/research/reengineering/rescue-repurpose/therapeuticuses/
directory.html).
In a meta-analysis with 800 subjects from 26 studies, glycine,
D-serine, and sarcosine had effect sizes ranging from 0.40 in
negative symptoms to 0.28 for cognitive and 0.26 for positive
symptoms, whereas D-cycloserine did not improve any symptom
domain. Interestingly, patients on risperidone or olanzapine, but
not clozapine, improved (Tsai et al., 2004).
Glycine directly activates the glycineB site on the NMDA-R,
but needs to be given in large quantities; D-serine is another
endogenous activator of the NMDA-R on a different binding site
and sarcosine was found to be a GlyT1 inhibitor (Wolkenberg and
Sur, 2010). The absence of target engagement data in these clinical
trials makes it difficult to interpret the clinical outcome.
Preclinical data on cognitive effects together with target
engagement studies in non-human primates for two GlyT1
inhibitors strongly suggest an inverse U-shape dose-response
(Eddins et al., 2014); in this study the highest doses consistently
failed to improve cognition and bitopertin was found to be effec-
tive only at the lowest and medium doses, but not at the highest
dose. An inverse U-shape dose-response is a difficult property for
any clinical trial development; although such a dose-response is
often observed in preclinical animal models, it is often difficult to
relate this to actual human target engagement levels. Therefore,
exploring the neurophysiology of such complex dose-responses
in a humanized translational model is of crucial importance to
drug development. In this report we will use an in silico quan-
titative systems pharmacology model (Geerts et al., 2013b) that
integrates preclinical information with clinical neuropathology,
imaging, and clinical data and that has been successful for cog-
nitive enhancements in schizophrenia (Geerts et al., 2013a) and
Alzheimer’s disease (Roberts et al., 2012; Nicholas et al., 2013) and
for motor side-effects of new antipsychotics (Geerts et al., 2012).
The remainder of the introduction will be devoted to the
biological rationale for identifying the brain regions and neuro-
physiological processes that play a role in the clinical phenotype
of negative symptoms. Unlike preclinical animal models, we
will use predominantly imaging studies from patients and their
relationship to clinical scales.
BIOLOGICAL RATIONALE FOR COMPUTER MODEL OF NEGATIVE
SYMPTOMS
Brain regions/neurophysiology involved in negative symptoms
The prefrontal cortex and ventral striatum are key brain regions
involved in the processing of negative symptoms. FromASL-fMRI
imaging studies to measure cerebral blood flow (CBF) in
schizophrenic patients on antipsychotics medications (Pinkham
et al., 2011), hypofrontality was most prominent in individu-
als with more severe negative symptoms. A large meta-analysis
of 25 imaging studies (Goghari et al., 2010) suggests an inverse
correlation between BOLD-fMRI activity of the ventromedial
cortex and the degree of negative symptoms. Metabolic activ-
ity, measured by PET imaging, is reduced as negative symp-
toms increase in patients without antipsychotics (Wolkin et al.,
1992) and physical anhedonia scale scores were negatively
correlated with the hypoactive dorsomedial PFC metabolism
(Park et al., 2009).
Another study suggests that activity of R. orbitofrontal cor-
tex, but not anterior cingulate correlates with the self-reported
Chapman Physical Anhedonia Scale (Harvey et al., 2010). As
anhedonia together with avolition and apathy form the more
“experiental” factor in negative symptoms, as opposed to flat
affect that is more “expressive” (Horan et al., 2011); this sug-
gests that lower activity of the R. orbitofrontal dysfunction might
play a role in negative symptoms.Moreover, an inverse correlation
of negative symptoms with R. anterior prefrontal cortex activity
at rest (Mingoia et al., 2012) suggests that basal cortical activity
is proportionally lower in patients with predominantly negative
symptoms but the identity of the cortical region depends upon
the task involved or the measurement condition.
This overview suggests that the cortical activity especially
of the vmPFC and the right orbitofrontal cortex is lower
in schizophrenia patients, and that increased activation might
correspond to improved symptoms.
Imaging studies of ventral striatum pathology in schizophrenia
(Menon et al., 2001; Harvey et al., 2010) suggest a profound and
proportional dysfunction, with more negative symptoms asso-
ciated with decreased activation level. In patients, lower ventral
striatum activation in patients is proportional to the severity of
negative symptoms, an effect that is independent of medication
(whether medication-free, on typical or atypical antipsychotics)
(Juckel et al., 2006a,b). In schizophrenia patients in psychotic
remission (Sorg et al., 2013) basal activity of the ventral striatum
is increased and this increase is correlated with improvements of
negative symptoms such as emotional withdrawal and blunted
affect.
Cellular localization of NMDA-NR2 subunits
The activity of the cortical region is driven by pyramidal cell
firing in general and by glutamatergic action in particular.
Therefore, NMDA-R is an interesting target for negative symp-
toms. However, because the cortical activity is defined by the
balance of excitation over inhibition, it is of interest to take into
account the differential localization of NMDA-R on pyramidal
cells and interneurons in cortical circuits. mRNA localization
studies of different NMDA-NR2 subunits in the rat and mice
hippocampus, suggest that NR2C/2D are localized on inhibitory
interneurons while NR2A/NR2B seem to be more concentrated on
pyramidal cells (Monyer et al., 1994). Functional evidence was
provided by elimination of NR2C subunit having no effect on
the strongly rectifying NMDA current in pyramidal cells of the
prefrontal cortex (Zhang et al., 2012).
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Reelin deficient heterozygous mice showed significantly
enhanced MK-801-induced locomotor hyperactivity and startle,
which was associated with significant up-regulation of NR1 sub-
units, but down-regulation of NR2C subunits in the frontal cortex
(van den Buuse et al., 2012), suggesting that loss of activity on
inhibitory neurons through reduced NMDA-NR2C synapses leads
to a lower GABA tone, a functional disinhibition, and a higher
locomotor activity. These and other preclinical data strongly
suggests that while NR2A and NR2B are expressed on pyrami-
dal excitatory cells, the NR2C subunit is localized on inhibitory
neurons.
Change of NMDA subunits with schizophrenia pathology
The NR2B subunit is upregulated during neurodevelopment
of the brain and is likely to play a relatively larger role in
schizophrenia, in line with the neurodevelopmental hypothesis
of schizophrenia pathology. Indeed in postmortem dorso-lateral
prefrontal cortex samples of schizophrenia patients vs. healthy
control, increased phosphorylation of NR2B at Y1336 is found
(Funk et al., 2012), probably leading to a higher functional activ-
ity by reducing endocytosis (Jiang et al., 2011; Li et al., 2011).
In patients with schizophrenia, a significant effect of GRIN2B
(human NMDA receptor 2B subunit gene, NR2B) genotype on
habituation (Hokyo et al., 2010) suggests a bigger role for NR2B
mediated processes.
Altered expression of mRNA for proteins involved in in
microtubule-associated tracking complex of NR2B such as
KIF17, APBA1, CASK, mLin7A, and mLin7C in cortical lay-
ers III and IV of schizophrenia patients, which overlapped
with NR2B but not NR2A transcripts suggests that NR2B-
containing NMDA receptor transport could be selectively com-
promised in schizophrenia (Kristiansen et al., 2010a,b). In
a subcellular endoplasmic reticulum (ER)-enriched fraction
from postmortem brain, ER expression of NR2B and PSD-95
was decreased in dorsolateral prefrontal cortex in schizophre-
nia. The data suggest that changes in NR2B processing in
schizophrenia involve increased ER exit of NR2B containing
NMDA receptors suggesting a higher membrane expression level
(Kristiansen et al., 2010b).
Furthermore, a cross-sectional study of over 900 human
brains from the publicly available BrainCloud website (http://
braincloud.jhmi.edu/) suggests an increase in cortical mRNA for
the NR2B subunit during the adolescent period (10–20 years) that
reverts for older brains. This suggests that during neurodevelop-
ment the NR2B subunit is upregulated in the human brain but its
expression tends to decrease with age.
In summary these data suggest that the NMDA- NR2B subunit
is upregulated in schizophrenia patients.
GLYCINE TRANSPORTER PHYSIOLOGY
In order to estimate the range of free glycine level that can be
readily achieved in the living human brain, we need to consider
the neurophysiology of the glycine transporter T1, found mostly
on astrocytes but also on neuronal cells and is a co-transporter
system driven by the electrogenic movement of 2 Na+ and 1 Cl−
over the cell membrane at a slow turnover rate of 10/s (Cherubino
et al., 2010). Kinetics followMichaelis-Menten dynamics with Km
in the range of 10–20 uM (Okamoto et al., 2009; Cherubino et al.,
2010).
The astrocyte membrane potential is in the range of −75mV
(Ma et al., 2014) and does not share the same temporal dynam-
ics as neuronal cells. The membrane can depolarize substantially
in the case of ischemic and traumatic brain injury (Strong and
Dardis, 2005), but we assume that the astrocyte membrane poten-
tial is close to the equilibirum value in schizophrenia.
METHODS
RECEPTOR COMPETITION MODEL
Many antipsychotic drugs on the market have different affinities
for multiple receptors, therefore calculating the receptor change
for a given exposure level of the drug at each of these receptors is
important, because they will affect the membrane potential of key
neuronal circuits and their emergent properties.
The receptor model simulates the competition between
endogenous neurotransmitter and up to four agents, (for instance
two drugs with their metabolites or a drug and radioactive tracer)
at postsynaptic receptors with full presynaptic autoreceptor cou-
pling to neurotransmitter release based on the affinities of the
drug for all receptors in the synaptic cleft (Spiros et al., 2010).
This is performed using a set of ordinary differential equations
that takes into account different neurotransmitter release patterns
and modulated by presynaptic autoreceptors, including presy-
naptic facilitation and depression processes. The dopaminergic
synapse is further calibrated (Spiros et al., 2010) using data on
dopamine dynamics measured with fast cyclic-voltammetry in
monkey slices (Cragg et al., 2000) and human cortical imag-
ing data (Slifstein et al., 2008), while the serotonin synapse with
5-HT1B as a presynaptic autoreceptor is calibrated using a com-
bination of preclinical fast cyclic voltammetry constrained by
human imaging data (Roberts et al., 2012).
The affinity parameters for each antipsychotic and neurotrans-
mitter for human receptors were derived from the in vitro exper-
iments performed at the Psychoactive Drug Screening Program
(PDSP) and reported in the PDSP database (http://pdsp.med.
unc.edu/indexR.html) with the advantage that the affinity val-
ues are derived under the same standardized assay conditions. For
different values of target engagement (e.g., D2R occupancy), we
then calculated the change of postsynaptic receptor activation for
all the receptors involved in the computer model based on the
affinities of the drug for different receptors.
CORTICAL-STRIATAL MODEL FOR NEGATIVE SYMPTOMS
Based on the human imaging studies, we developed a dual
cortical-striatal model for the neurobiology of negative symp-
toms (Figure 1). The cortical neuronal network consists of 20
excitatory neurons and 10 inhibitory interneurons and has been
described before (Geerts et al., 2013a). This model has been cal-
ibrated from in vivo single-unit recordings in primates during a
working memory task and reduces some of the problems associ-
ated with species difference in inhibitory tone. Synchronous firing
of the target pyramidal cells is initiated by injecting a transient
current at t = 2000ms. The network then fires in a synchro-
nized pattern before it gets degraded by the background noise
and the interference of the distractor neurons. The simulated
www.frontiersin.org October 2014 | Volume 5 | Article 229 | 3
Spiros et al. Computer model for negative symptoms in schizophrenia
FIGURE 1 | Schematic description of the two-part quantitative systems
pharmacology model for negative symptoms of schizophrenia. The
BOLD-fMRI signal of a neuronal cortical circuit (top) is calculated after
implementing a representation of the schizophrenia pathology and the
effect of glycine modulation. This is combined with the glycine BOLDfMRI
effect through the afferent NMDA-dependent projections of the cortical
input in a model of the ventral striatum medium spiny neuron (bottom).
Combining the output of these two models results in a weighted readout
that is a human imaging based proxy for the clinical phenotype of
negative symptoms. While currently marketed antipsychotics exert their
effects on PANSS negative mainly through the ventral striatum part,
glycine modulation acts mostly through the cortical network. The
simulation of historical trials with the appropriate drug-dose relationship of
currently marketed antipsychotics in this model and comparison with the
reported clinical changes on the PANSS negative subscale provides a
calibration relation where the anticipated clinical effect of new therapeutic
interventions can be predicted from the outcome in the computer
model.
neural activity represents the right orbitofrontal cortex or the
vmPFC.
Functional representations, driven by preclinical experiments
on the coupling between receptor activation and changes in
voltage-gated ion channel conductance, of the dopamine (D1,
D2, D3, D4, DAT, COMT), serotonin (5HT1A, 5HT1B, 5HT2A,
5HT2C, 5HT3, 5HT4, 5HT6, SERT), norepinephrine (alpha1A,
alpha2A, NET), cholinergic (M1 mAChR, M2 mAChR, α7
nAChR, α4β2 nAChR, and AChE), glutamate NMDA (different
subunits NR2A-NR2B-NR2C), AMPA,mGluR2,mGluR5, GlyT1,
GABA-A α1 and GABA-A α2, histamine H3 and PDE-10 targets
are currently implemented in the model.
Although the intracellular pathways activated by receptor
modulation are not modeled in full detail, we implement the
effects as a transfer function on ion channel permeability or
transporter functionality. For instance a change in dopamine
D1R activation on cortical neurons is implemented by changing
the slow K+ channel Iks conductance (Yang and Seamans, 1996)
and the High-voltage activated (Hva) Ca++ -channel, based on
preclinical electrophysiological measurements (Law-Tho et al.,
1994).
Schizophrenia pathology in the cortical network is intro-
duced as a reduction in glutamate tone (Coyle, 2006), decreased
dopamine tone (Meyer-Lindenberg et al., 2002; Weinberger,
2007) in the cortex, impaired GABA physiology through a
decrease in GAD67 activity resulting in lower GABA release
(Gonzalez-Burgos et al., 2010) and increased background noise
level (Winterer et al., 2000). Such a pathology when implemented
in the computer model leads to a deterioration of a marker for
cognitive outcome of about 1.5 standard deviations (Geerts et al.,
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2013a). In this case, rather than the length of time a certain fir-
ing pattern can be independently held, the cortical readouts of
the model for negative symptoms of schizophrenia is the average
firing rate and BOLD-fMRI.
The ventral striatum model has been described in detail
as part of the quantitative systems pharmacology platform for
schizophrenia (Geerts et al., 2012; Spiros et al., 2012). Briefly,
the model calculates the excitability of the medium spiny neuron
(MSN), the major GABA-ergic cell type in the nucleus accum-
bens, when driven by afferent cortical projections and gated by
both hippocampal and amygdala projections. Changes in mem-
brane potential are calculated using partial differential equations
that are solved in NEURON (Hines and Carnevale, 1997). If
C is the membrane capacitance, then the time course of the
membrane potential V can be determined from the following
equation:
C
∂V
∂t
= IKsi + IKA + .ICl + ICa + . . . (1)
where IX is the current associated with channel X.
We simulate three types of neuronal MSN cells: SP+ = D1R+
cells that project to the direct pathway; Enk+ = D2R+ cells that
project to the indirect pathway; and a small number of D+1 D
+
2
cells that project to both pathways. In the SP+ cells the D1R
mostly affects the Kir2 channel and increases the L-type Ca++
current (Hernandez-Lopez et al., 2000), while in Enk+ cells, D2R
activation affects the A-type K+ current (Falk et al., 2006). In
addition, D2R activity modulates the presynaptic Glu release on
the afferent cortical fibers (O’Donnell and Grace, 1994; Bamford
et al., 2004).
For instance, the inward rectifying potassium current, Kir2,
is modified by the dopamine D1R activation u (Kuzhikandathil
and Oxford, 2002; Falk et al., 2008) so that the total current,
I = u · IKir2. With a conductance, gK , and a reversal potential,
EK = −90mV, the current is given by IKir2 = gK (V − EK) with
a voltage dependent form
gK = g¯K 1
1 + exp
(
−V−VKh
VKc
) (2)
where g¯K = 1.2mS/cm2 is the maximum conductance,
Vh = −111mV is the value of the membrane potential that
causes half activation and Vc = −11mV describes the sensitivity
of the change (Mermelstein et al., 1998; Gruber et al., 2003).
The amount of DA released in the striatal dopaminergic
synapse is increased by 5-HT2C receptor inhibition (Abdallah
et al., 2009), while 5-HT3R antagonism decreases striatal DA
(De Deurwaerdere et al., 1998; Porras et al., 2003). Cholinergic
modulation affects the excitability of MSN through an effect on
Cl- channel (Shen et al., 2005, 2007) through postsynaptic M1R
mAChR. In addition, M2 mAChR located on corticostriatal ter-
minals (Hersch et al., 1994) inhibit the glutamatergic input to
MSNs (Malenka and Kocsis, 1988; Sugita et al., 1991; Calabresi
et al., 1998; Hernandez-Echeagaray et al., 1998). Adrenergic
alpha1A-R block decreases gating signal stimulation of the GABA
spiny neuron (Braga et al., 2004; Aroniadou-Anderjaska et al.,
2007). All these processes are implemented using the appropri-
ate differential equations with a linear relationship between the
increase of DA and normalized activation level.
IMPLEMENTATION OF THE BOLD-fMRI READOUT
In order to calculate a measure of the BOLD-fMRI outcome from
the computer model, we implemented a series of biophysical
relations between excitatory and inhibitory neuronal activity as
determined by experimental studies (Sotero and Trujillo-Barreto,
2007, 2008). The relevant equations are implemented describ-
ing the relationships between excitatory and inhibitory neuronal
activity, glucose consumed, oxygen consumed, and CBF changes
to obtain a measure of the BOLD signal with the Balloon model
(Buxton et al., 2004; Buxton, 2012) with the parameters provided
from a review study (Sotero and Trujillo-Barreto, 2008).
With v(t) the normalized cerebral blood volume, f (t) the
normalized CBF and q(t) the doxyhemoglobin content, the
BOLDfMRI signal y(t) is described by
y (t) = V0(a1
(
1 − q) − a2(1 − v) (3)
With
dv (t)
dt
= 1
t0
(f (t) − fout (v, t) ) (4)
dq (t)
dt
= 1
t0
(m (t) − fout (v, t) q (t)
v (t)
) (5)
fout (v, t) = v exp
(
1
a
)
+ τdv(t)/dt (6)
Furthermore, with me(t) and mi(t) the metabolic rate of oxygen
consumption from excitatory and inhibitory cells, respectively
m (t) = (γme (t) + mi (t) )/(γ + 1); (7)
mi (t) = gi(t) and me (t) = ge(t)(2 − x (t) )/(2 − xo) (8)
And g (t) = (2γ ge (t) + (2 − xo) gi (t) )/(2γ + 2 − xo) (9)
With ue(t) and ui(t) the excitatory and inhibitory neuronal activ-
ity, both ge(t) and gi(t), the glucose level normalized to baseline
consumption, are further defined by
dge (t)
dt
= se (t) (10)
and
dgi (t)
dt
= si(t) with
dse (t)
dt
= ae (ue (t − δe) − 1)
τe
− 2se (t)
τe
− ge (t) − 1
τe ∗ τe (11)
With an identical equation for si(t) with all indexes referring to
inhibitory interneuron activity ui(t).
The CBF f(t) is defined by df (t)dt = s(t).
Where ds(t)dt = ε
(
ee
(
t − δf
) − 1) − s(t)
τs
− (f (t) − 1/τf .
Values for the different constants are given in Table 3 of Sotero
and Trujillo-Barreto (2008). For instance, ae is the efficacy of glu-
cose consumption response to excitation (1.2); c the steepness of
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the sigmoid function (2.5) and d the position of the threshold
for the sigmoid function (1.6), τ the time constant that controls
how fast Cerebral Blood volume adjusts to changes in CBF (10 s),
a1 weight for deoxyhemoglobin change (3.4) and a2 weight for
blood volume change (Rosenbaum et al., 2012).
IMPLEMENTATION OF THE GLYCINE NEUROPHYSIOLOGY IN THE
MODEL
The ratio of NR2A/NR2B subunit on pyramidal excitatory
synapses vs. NR2C/NR2D subunit on inhibitory cells is an impor-
tant driver of glycine modulation. Glycine interacts differently
with different NMDA-NR2 subtypes even if the binding site is on
the NR1 subunit. The potentiation of NMDA current by glycine
has been measured experimentally and can be described by a
Hill equation. The NMDA-R conductance g can be described as
follows.
g = gmax [Gly]
n
[Gly]n + [EC50]n (12)
With gmax a maximal conductance value, [Gly] the concentra-
tion of extracellular glycine and with numerical values for EC50
and Hill slope determined from a number of experimental studies
(Kutsuwada et al., 1992; Laurie and Seeburg, 1994; Matsui et al.,
1995; Woodward et al., 1995; Chen et al., 2008).
The EC50 (concentration at which effect is 50% of maximum)
and Hill slopes (n) for different experimental conditions are given
in Table 1. It will be clear that with different values for the Hill
equation and EC50 we get rich dynamics in terms of the ratio of
the NMDA currents on pyramidal-pyramidal synapses (mostly
NR2A-NR2B) vs. the NMDA currents on pyramidal-inhibitory
synapses driven by the NR2C-NR2D subunits (see Figure 3 for
example).
Table 1 | Experimentally determined values for EC50 and Hill slopes
for glycine-glycine site interaction on the NMDA-NR2 subunit from
different experimental conditions.
Parameter NR2A NR2B NR2C NR2D References
EC50 (uM) 0.97 0.84 0.75 0.56 Matsui et al., 1995
Hill slope 1.5 2 2 1
EC50 (uM) 2.1 0.3 0.2 Kutsuwada et al., 1992
Hill slope 1.5 1.5 1.5
EC50 (uM) 0.84 0.19 0.15 0.096 Woodward et al., 1995
Hill slope 1.5 2 1.5 1
EC50 (uM) 3.7 2.1 0.36 2.3 Laurie and Seeburg, 1994
Hill slope 1. 1.5 1.5 1.5
EC50 (uM) 1.31 0.72 0.34 0.13 Chen et al., 2008
Hill slope 1.66 1.84 1.81 1.32
Average EC50 (uM) 1.78 0.83 0.36 0.77
Average Hill slope 1.43 1.77 1.66 1.21
EC50 values are definitely higher and there is a trend for higher Hill slope for
excitatory-excitatory NR2A/B subunits (especially when considering the NR2B
subunits) over the excitatory-inhibitory NR2C/D subunits.
CALIBRATION OF THE MODEL WITH CLINICAL DATA ON NEGATIVE
SYMPTOMS
The model is subsequently calibrated using historical clinical
trials. Historical clinical data in schizophrenia patients were col-
lected by querying PubMed with the keywords “drug X” and
“schizophrenia” and trial” in the period since 1986. Restricting
the data to clinical double-blind placebo-controlled studies on
drug monotherapy using stable schizophrenia patients for a short
duration (4–12 weeks), resulted in 91 papers and 71 drug-dose
combinations. For each drug dose combination, we calculated
the change in postsynaptic receptor activation using the recep-
tor competition model using the appropriate affinities of the
neurotransmitter, the drug and its metabolite.
We assume a linear normalized relationship between receptor
activation and biological effect on physiological responses such
as X
eff
Y = X
A
Y −XCY
XCY
; (Equation 13) where XAY and X
C
Y are the actual
activation levels of receptor X subtype Y (for instance D1) after
treatment (A) and the untreated (placebo) control levels (C).
Such short clinical studies are common in the clinical test-
ing of antipsychotics and motor side effects can arise very early
with treatment. For each study, the average outcome of a patient
group on the reported clinical trial was entered into a database.
In the case of multiply reported results for the same drug-dose,
the weighted average outcome based on number of patients was
calculated. The list of clinical studies can be requested from the
corresponding author.
RESULTS
CALIBRATION OF THE MODEL FOR NEGATIVE SYMPTOMS OUTCOME
Extraction of the relevant information from the clinical database
results in 34 drug-dose combinations of short-term clinical trials
FIGURE 2 | Correlation between model outcome and changes on
PANSS negative clinical scale for 34 drug-dose combinations derived
from the literature since 1988 on pivotal Phase III or head-to-head
comparison trials. For each drug dose-combination, the appropriate target
engagement (derived from PET radiotracer displacement studies) and
pharmacology against human receptors was used to calculate the impact
on changes in all postsynaptic receptors in the model, leading to changes in
BOLDfMRI readout of the cortical part of the computer model and activity
in the ventral striatum computer model. A weighted sum of these two
parameters (40% cortical input and 60% ventral input) was defined as a
proxy for negative symptoms. In addition, a few biological coupling
parameters in the ventral striatum model were adjusted to achieve a robust
correlation between model results and clinically reported outcomes.
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FIGURE 3 | (A) Relative currents through NMDA- NR2C/D subunits in
pyramidal-inhibitory glutamatergic synapses (e-i) over NMDA currents and
NMDA- NR2A/B subunits in pyramidal-pyramidal glutamatergic synapses
(e-e) and the ratio of NR2C/D over NR2A/B currents as a function of glycine
concentration. This particular graph corresponds to a value of 0.35 and
0.25 uM for EC50 of NR2A/B and NR2C/D respectively and a Hill coefficient
of 1.84 and 1.1 for NR2A/B and NR2C/D respectively. This particular case
shows a minimum of 0.93 on the ratio of NR2C/D over NR2A/B at a glycine
concentration of 1.1 uM. For certain combinations of the EC50 and Hill
coefficients of the interaction between glycine and its binding site on
NMDA receptors, the ratio shows a U-shape dose-response. For glycine
concentrations where the e-i over e-e ratio drops below 1 (in this case
between 0.5 and 30 uM), this leads to a relative dominance of the
excitatory tone over the inhibitory tone and a greater firing and BOLD-fMRI
outcome. (B) Dose-response of the model outcome for negative symptoms
as a function of glycine concentration for different combinations of
parameters for glycine-NR2C/D vs. glycine-NR2A/B interactions after
calibration with clinical data. The parameter settings are EC50 for NR2C/D,
Hill coefficient for NR2C/D, EC50 for NR2A/B, Hill coefficient for NR2A/B,
respectively so that the conditions shown are A (0.2 uM, 0.7, 0.3 uM, 1.7); B
(0.2 uM, 1, 0.22 uM, 1.5); C (0.21 uM, 1, 0.25 uM, 2); D (0.2 uM, 1, 0.35 uM,
2); and E (0.20 uM, 1.46, 0.35 uM, 1.78). In a clinical trial, glycine
concentration can be altered using either a glycine transporter inhibitor or
substitution with glycine. Note the inverse U-shape dose-response that
parallels the ratio of current through the NMDA-NR2 subunits located at the
excitatory-excitatory synapses over the current through the NMDA-NR2
subunits located at the excitatory-inhibitory synapses. Maximal effect is in
the two-point range but is only obtainable if the typical glycine
concentration is around 1 uM. With higher glycine concentration, in many
cases the effect decreases, with a worsening of negative symptoms in
some cases for glycine concentrations greater than 5 uM.
(4–12 weeks) with outcomes on the PANSS negative subscale.
Each of these drug-dose combinations was then first simu-
lated with the appropriate PET tracer displacement (with 11C-
raclopride) studies in the dopamine receptor competition model
to yield the functional intrasynaptic drug concentration that
corresponded to the observed tracer displacement. These func-
tional drug doses were then applied to the receptor competition
model for all postsynaptic receptors (other dopamine recep-
tors, in addition to serotonergic, cholinergic, and norepinephrine
receptors) in the computer model using the appropriate pharma-
cological interaction between that particular drug and the human
receptor subtype. With the resulting changes in postsynaptic
receptor activation for all synapses in the negative symptoms
QSP computer model, in silico computer model results were
obtained for each drug-dose combination, in particular changes
in BOLDfMRI readout of the cortical part of the computer model
and activity in the ventral striatum computer model. A weighted
combination of these two parameters was then defined as a proxy
for negative symptoms.
Those results were then compared to the corresponding actual
clinical readouts on PANSS Negative. Figure 2 shows the corre-
lation between the model outcome of these drug-dose combina-
tions and the actual reported changes in PANSS Negative. A few
biological coupling parameters in the ventral striatummodel were
adjusted to achieve a robust correlation. The observed correla-
tion suggests that the model captures a substantial part of the
variance.
DOSE-RESPONSE OF GLYCINE MODULATION
In order to simulate the effect of modulating glycine concentra-
tion on the network outcome, we proceeded by calculating the
Hill equations for the interaction between glycine and the NR2
subunit on the excitatory-excitatory (e-e) glutamatergic synapses
withNMDA subunits (NR2A-NR2B) and the excitatory-inhibitory
(e-i) glutamatergic synapses with NMDA subunits NR2C-NR2D.
Figure 3A shows the currents through the two synapse types
and their ratios as a function of glycine concentration. Due to
the complex non-linear effects, for a number of EC50 and Hill
coefficient parameter settings, the ratio of inhibitory to excita-
tory NMDA response decreases, reaches a minimum and then
increases again, allowing for a complex non-monotonic dose-
response. The range of EC50 and Hill coefficient parameters for
which this can be observed is examined in the following section.
When entering these changes for the effect of glycine on e-
e and e-i glutamatergic synapses as corresponding changes in
NMDA maximum conductances on the respective synapses, the
impact on the output of the network can be calculated. Figure 3B
shows the anticipated clinical outcome on the PANSS negative
scale based on the calibration (Figure 2) for a number of com-
binations of the interaction parameters between glycine and its
binding site on the NMDA receptor. The clinical benefit fol-
lows an inverse U-shape dose-response relationship with the free
glycine concentration provided that the typical glycine concentra-
tions are less than 0.5 uM, very similar to the dose-response of the
ratio of the currents, NR2C/2D to NR2A/2B NMDA subtypes. In
fact using a number of different values for the EC50 and Hill coef-
ficient parameters, we can confirm the correspondence between
these two dose-responses (data not shown).
Although the dose-responses in general are similar for the dif-
ferent glycine interaction parameters, the glycine concentration
for which there is a clinical benefit varies substantially. As no
experimental data are available for the interaction of glycine with
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the glycine binding site in the living human brain, in principle
accordance between the model outcome and the clinical results
will help to narrow down the range of likely parameters. In the
following section we will address these issues in more detail.
SENSITIVITY OF THE MODEL TO BIOLOGICAL COUPLING AND
PHYSIOLOGY PARAMETERS
We then studied the sensitivity of the model outcome as a func-
tion of small changes on all possible parameters, including the
changes that reflect the implementation of the schizophrenia
pathology. This could be envisaged as the intrinsic variability
in a large set of patients possibly driven by the appearance of
genotypic changes in neurophysiological and neuropathological
pathways. For this we allowed the parameter to change by a cer-
tain fraction around their calibrated value. A general effect size is
calculated by dividing the difference between the maximum and
minimum relative effects by the fractional range in parameter set-
tings. From the outcomes reported in Table 2, it is clear that the
changes in pathology implementation at the level of the cortical
network lead to the largest changes in the results. The effect of
the parameters on the Hill equations for the interaction between
glycine and its binding site on the NMDA-R will be explored in
detail in the following section.
SENSITIVITY ANALYSIS ON GLYCINE HILL EQUATION
A crucial set of parameters is the relative values of the EC50 and
Hill coefficients for the glycine-NMDA current effect through the
Table 2 | Sensitivity of the model outcome for different parameters
and coupling constants that are changed between 20 and 50% in
both directions for the glycine dose-response.
Sensitivity Minimal Maximal Effect
range (%) effect (%) effect (%) size
INTERACTION GLYCINE
EC50 on inhibitory
neurons
−50 to +50 −18.6 20.7 0.393
Hill slope on inhibitory
neurons
+50 to −50 −22.1 13.4 0.355
EC50 on excitatory
neurons
+50 to −50 −14.1 38.9 0.530
Hill slope on excitatory
neurons
−50 to +50 −18.4 14.3 0.327
CORTICAL SZ PATHOLOGY
NMDA reduction +20 to −20 −37.7 18.2 1.398
GABA reduction −10 to +10 −32.4 20.8 1.620
DA deficit −41 to + 41 −7.9 2.8 0.130
Noise increase +24 to −24 −13.9 18.5 0.675
STRIATAL PHYSIOLOGY
DA receptors +20 to −20 −9.3 10.1 0.485
Muscarinic receptors −20 to +20 −3.5 15.6 0.478
Maximal and minimal effect on the dose-response are derived. The general
effect size is calculated as the difference between maximal and minimal out-
come divided by the input range. The data suggest that GABA and NMDA
reduction have a big impact on the outcome, likely because they are driving
the baseline excitation-inhibition balance upon which glycine modulation will act.
different NR2 subunits. As shown in the previous section, the
inverse U-shape dose-response in the cortical network outcome
corresponding to a clinical benefit on PANSS negative is asso-
ciated with a U-shape dose-response of the ratio of inhibitory
over excitatory effect (compare Figure 3A with Figure 3B). Note
that the glycine concentration for maximal effect on the network
corresponds to the glycine concentration of the minimum in the
ratio of NR2C/D over NR2A/B.
Because the experimentally determined values reported in
Table 1 for the interaction of glycine with the humanNMDANR2
subunits were performed in an artificial in vitro system and could
be quite different from the actual human in vivo situation, we sys-
tematically studied the effect of changing the values for EC50 on
the network outcome.
Figure 4 shows the sensitivity analysis when probing different
parameter ranges for EC50 and Hill coefficients of the interac-
tion between glycine and the NMDA-NR2 subunits. It is clear
that higher Hill coefficients for the NR2A/B subunits compared
to the NR2C/D subunits is necessary for a beneficial effect on
the network outcome with the range increasing with larger dif-
ferences between the Hill coefficients for NR2A/2B vs. NR2C/2D
subunits.
PHYSIOLOGICAL RANGE OF GLYCINE CONCENTRATION
The free glycine concentration in the human brain is regu-
lated by a 2Na+-Cl−-Gly co-transporter system and its value
is constrained by the Nernst-Goldman equation. Therefore, the
functional free glycine concentrations in steady-state equilib-
rium conditions is dependent upon the range of concentrations
for intracellular and extracellular Na+ and Cl−. Assuming the
glycine transporter is located on astrocytes, all calculations are
done for astrocyte membrane potential and intracellular ion
concentrations. Astrocyte membrane potential, while not chang-
ing on the same time scale as neuronal membrane potential is
supposed to be in the −50 to −70mV range for steady state
conditions.
With the exception of extreme pathological situations such as
in stroke or neurotrauma, Na+ and Cl− ion concentrations in the
human brain are tightly regulated. Figure 5 shows a number of
solutions to the Nernst-Goldman equation for different ranges of
intracellular Na+ and intracellular glycine concentrations. All fig-
ures are derived for constant values of intracellular Cl− of 6mM
and extracellular Cl− concentration of 120mM. It is clear that in
the absence of extreme pathology, the range of free extracellular
glycine is limited and is unlikely to exceed 10 uM.
INTERNALIZATION OF NMDA-R AT HIGH GLYCINE CONCENTRATIONS
High glycine exposure in principle could overstimulate the
NMDA-R and lead to epileptic seizures. In preclinical slice work,
NMDA-R internalization has been observed at very high glycine
concentrations, typically with an EC50 value in the range of
40 uM (Nong et al., 2003). While the Nernst-Goldman equations
that regulate the free glycine concentration as a function of free
Na and Cl strongly suggest that glycine concentrations beyond
5 uM are highly unlikely (see Figure 5), we nevertheless simulated
the effect of NMDA-NR2 subunit internalization on the computer
model outcome.
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FIGURE 4 | Sensitivity analysis of the inverse U-shape dose-response
for glycine-dependent outcome of the computer model as a function
of the Hill slope and the EC50 values for both classes of NMDA-NR2
subunits. The x-axis represents EC50 values for the e-i NR2C/D subunits
and the y-axis represents the EC50 values for the NR2A/B subunits. Shown
are ratios of different Hill coefficients on NR2A/Bvs. NR2C/D subunits:
(A) 1:1, (B) 1.25:1, (C) 1.5:1, (D) 1.75:1, and (E) 2:1. Combinations of values
in green color are associated with a U-shape dose-response for NMDA
effects of e-i over e-e with a minimum between 0.5 and 10 uM of glycine
concentration and therefore a beneficial effect on the network outcome.
Combinations in yellow are associated with values resulting in monotonic
decrease of the ratio and combinations in blue are associated with a
non-biological minimum much smaller than 0.5 uM. The results indicate
that a beneficial inverse U-shape dose-response on negative symptoms is
associated with large differences between the Hill coefficients for NR2A/2B
vs. NR2C/2D subunits. In addition, in most cases, a beneficial inverse
U-shape dose-response is associated with greater EC50 values for NR2A/2B
than for NR2C/2D.
We simulated two conditions of internalization (Figure 6).
The first condition assumes the same EC50 value (40 uM) for both
NR2A/B subunits as for NR2C/D subunits. As expected, for very
low levels of glycine where the internalization process has a very
limited effect, the dose-response shows a peak for glycine levels in
the low uM range. The results further suggest that internalization
of the NMDA-R assuming the same EC50 values for the two types
of NR2 subunits leads to a substantial decrease (corresponding
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FIGURE 5 | Relationship between Na+-concentration,
Cl−-concentration and glycine concentration based on the
Nernst-Goldman equation that constrains the 2Na+-Cl−-Gly
co-transporter system. (A) Extracellular glycine concentration as a
function of membrane potential for different values of intracellular Na+
keeping Glyi fixed at 2mM; (B) extracellular glycine concentration as a
function of membrane potential for different values of intracellular glycine
keeping Na+i fixed at 15mM. All figures are derived for constant values of
intracellular Cl− of 12mM and extracellular Cl− concentration of 120mM.
With values of Na+i in the range of 10–20mM and membrane potential
between −70 and −40mV, this analysis suggests that extracellular glycine
concentrations are limited to a range between 0.5 and 2–3 uM.
to a collapse of network activity at glycine levels beyond 20 uM).
The second assumption assumes that the internalization process
would have the same affinity as glycine itself, i.e., an EC50 of
32 uM for the NR2A/B subunits and an EC50 of 50 uM for the
NR2C/D subunits. In that case, the simulations suggest that the
model outcome first improves beyond the no internalization case
before collapsing at glycine levels beyond 40 uM.
DISCUSSION
This report describes a quantitative systems pharmacology com-
puter model based on physiologically realistic interactions in
models of a cortical network and the ventral striatum. The major
result of this simulation is the prediction of an inverse U-shape
dose-response with glycine that is a consequence of the shifting
balance between excitation and inhibition in the cortical net-
work, secondary to an interesting difference in pharmacological
properties of glycine for the different NMDA subunits regulating
excitatory and inhibitory tone.
The sensitivity analysis suggests that there are a substantial
number of parameter combinations that result in such an inverse
FIGURE 6 | Effect of NMDA-R internalization under the hypothesis that
high levels of glycine are possible and using the experimental data
from (Nong et al., 2003). Two conditions of internalization are simulated:
INT-1–EC50 (40-40) assumes the same EC50 for internalization of NR2A/B
subunits as for NR2C/D subunits (40 uM); INT-2–EC50 (50-32) assumes the
EC50 for internalization of the NR2C/D is lower (32 uM) than for the NR2A/B
subunit (50 uM) in accordance with the relative difference in EC50 for
glycine to the glycine binding site. INT-1 is similar to the situation without
internalization reaching a peak for glycine levels in the low uM until the
network starts to collapse around a value of 20 uM. With INT-2, the model
outcome reaches a similar early peak for glycine levels in the low uM that
drops off before it begins to improve (at 10 uM) before collapsing at a
glycine level beyond 40 uM.
U-shape dose-response with glycine. The exact values for the
interaction in the human brain is unknown and probably is
different for each subject, but in general an inverse U-shape
dose-response can be achieved when both the EC50 and the Hill
coefficient for the glycine effect on the NR2C/D subunit is lower
than for the NR2A/B subunit. It is of interest to note from different
experimental data that on average the interaction of glycine with
the NMDA-NR2B subunit indeed suggests a higher value for the
Hill coefficient. As noted in the Biological Introduction, the neu-
rodevelopmental trajectory of schizophrenia tends to delay the
appearance of the mature NMDA-NR2A subunit, so that there is a
relatively higher contribution of the NMDA-NR2B subunit to the
excitatory tone in schizophrenics. This allows the interaction of
glycine with the e-e NMDA receptor to have a higher Hill slope
in combination with a lower EC50 concentration, promoting an
inverse U-shape dose-response.
The clinical Phase II data with the glycine inhibitor bitopertin
suggest indeed that the clinical outcome follows such as dose-
response. Some studies with D-serine, D-sarcosine or glycine
have often reported mixed effects (Singh and Singh, 2011), with
some but not all showing a clinical benefit and the interpretation
is hampered by the lack of data on proper target engagement.
It is conceivable that this could be a consequence of the non-
linear dose-response with patients on different points of the
dose-response. It is also of interest to note that negative symp-
toms seem to be most improved when glycine or D-serine levels
are increased (Singh and Singh, 2011). The QSP platform when
calibrated suggests a rather limited effect of glycine modulation
on clinical changes in PANSS negative in the range of 2–2.5
points. Note that the patient population used for calibration was
not selected for extremely high negative symptomatology, result-
ing in a baseline PANSS negative between 18 and 24. Although
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this observed change is in line with published data on gluta-
matergic modulation (Singh and Singh, 2011), it suggests that
such a limited effect might be difficult to be detected in clinical
situations.
These results also lead to the important observation that
because of the different contribution of the NMDA-NR2 sub-
units, the interaction between glycine and the NMDA recep-
tors likely is different in healthy volunteers as compared with
schizophrenia patients. Such a difference is extremely difficult to
achieve in preclinical animal models. Therefore, great care needs
to be taken to extrapolate positive or negative findings from a
Phase I proof-of-concept study in healthy volunteers to actual
schizophrenia patients.
Similarly, rodent models often lack the right mix of NMDA
receptor subtypes to simulate very well the actual pathology
mediated and often do not show the inverse U-shape dose-
response (Alberati et al., 2011). Not realizing this could substan-
tially hamper the clinical development and often can lead to failed
clinical trials. In addition, clinical trials have been performed
as augmentation strategy, i.e., the glycine modulator interven-
tion is given to patients on stable antipsychotic medication. Such
comedications can have a direct effect through affecting the
metabolism of the active compound which is dependent upon
the genotype of the specific Cytochrome P450 enzyme but can
also be modified by other comedications such as nicotine (Tsuda
et al., 2014). The comedications can also have an indirect effect on
the dose-response of glycine level modulation through non-linear
interactions on the excitation-inhibition balance that affect the
emergent properties such as the BOLD-fMRI signal. This paper
does not address the issue of comedication, but we are planning
to perform such an in-depth analysis in a follow-up paper.
LIMITATIONS OF THE MODEL
Firstly, different reports suggest that D-serine plays amore impor-
tant role as co-agonist on the NMDA-R in the cortex (Fossat et al.,
2012) while other studies suggest a role for both D-serine and
glycine in regulating neuronal morphology in rodent somatosen-
sory cortex (Balu et al., 2012). To a certain extent, the interaction
of D-serine with the co-agonist site on the NMDA-R is quite sim-
ilar to glycine’s interaction (Chen et al., 2008), but the level of
free D-serine is regulated by serine racemase localized in neurons
(Balu et al., 2014) and by a Na+-independent alanine-cysteine-
serine transporter system (Maucler et al., 2013). This suggests
that most of the conclusions for glycine, with the exception of
the limited range of glycine driven by its specific Na+-dependent
co-transporter system can be applied to the modulation of
D-serine.
There is also some discussion about the nature of the NMDA
NR2 subunits on the inhibitory cell types in cortical networks.
mRNA studies in the human brain localize the NR2C subunit
predominantly to the cerebellum (Monyer et al., 1992) although
there are lower levels present in the cortex (Allen Brain institute
data http://human.brain-map.org/). However, NR2D subunits are
likely present in cortical areas on excitatory-inhibitory synapses
and could play a predominant role in the generation of the
inhibitory tone. The exact interaction parameters between glycine
and its co-agonist binding site on the NMDA receptor in the
human brain are unknown, but the computer model suggests
a range of interaction parameters that would correspond to an
inverse U-shape dose-response. Although adding a greater con-
tribution of NR2D to the inhibitory tone will increase the EC50
of the e-i interaction, it will also decrease the Hill coefficient
as compared to the interaction of glycine with the e-e synapses,
which has been shown to be favorable for an inverse U-shape
dose-response.
The model presented here does not address the other mod-
ulatory agents such as extracellular proteins, zinc, polyamines,
and neurosteroids. All these molecules can influence the dynam-
ics of glycine-mediated amplification of NMDA-currents and we
assumed that these modulators do not change in schizophrenia.
In principle, if new data become available suggesting a change in
these neuromodulators as a consequence of schizophrenia pathol-
ogy, detailed biochemical data could be incorporated in this
platform to estimate their impact.
In summary, this report simulates the anticipated dose-
response of glycine level modulation on an emergent property
(BOLD-fMRI) of a computer-based neuronal circuit that has
been calibrated against clinical outcomes for negative symptoms.
It provides a physiological explanation for the appearance of
an inverse U-shape dose-response based on a biologically con-
strained set of interaction parameters between glycine and the
co-agonist site on different types of NMDA-NR2 subunits and
the electrogenic character of the Gly/2Na/Cl co-transport sys-
tem. A notable limitation is that this study deals with the effect
of glycine modulation in the absence of any antipsychotic med-
ication and therefore does not reflect the real clinical study
design.
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